A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of PRX003 Administered by Intravenous Infusion in Healthy Subjects

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of PRX003 Administered by Intravenous Infusion in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Nov 2016

At a glance

  • Drugs PRX 003 (Primary)
  • Indications Psoriasis
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Prothena
  • Most Recent Events

    • 09 Jun 2016 Results published in Prothena Corporation media release.
    • 09 Jun 2016 Results from this study presented at The European League Against Rheumatism (EULAR) 17th Annual European Congress of Rheumatology, as per Prothena Corporation media release.
    • 14 Mar 2016 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top